GPT and metabolic dysfunction-associated steatotic liver disease: The JGXZ group had lower TG, TC, ALT, and AST levels after treatment and improved liver pathological alterations, which suggests that JGXZ has a therapeutic impact on NAFLD, which is consistent with our previous research findings.